AlphaYou
Overview
Smart money at a glance
Filings to Oct 11, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 4 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 11- Open
- $10.42
- 52-wk high
- $28.23
- High
- $10.42
- 52-wk low
- $9.76
- Low
- $9.76
- Prev close
- $10.53
- Mkt cap
- $1.51B
- Volume
- 1.53M
- P/B
- 1.5x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -36.9%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about KLRA filings
Are insiders buying or selling Kailera Therapeutics, Inc. Common Stock (KLRA) stock?
Neither. Kailera Therapeutics, Inc. Common Stock (KLRA) insiders filed no open-market purchases or sales in the 90 days to Oct 11, 2026, according to SEC Form 4 filings.
Which members of Congress have traded KLRA recently?
None. No member of Congress disclosed a KLRA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this KLRA smart-money data?
This summary uses filings available on Oct 11, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net buying.
What funds are doing
What insiders are doing
Buys (3)
- RI
Rtw Investments, Lp
$8.0M
bought
- BC
Bain Capital Investors Llc
$134.4M
bought
- KA
Kaplan Andrew T.
$134.4M
bought
How top traders are positioned
No tracked top-trader positions in KLRA right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No earnings history.
Reports Nov 11, 2026, in 31 days
Financials
What it sold, what it cost, what was left.
| USD | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| What it spent | ||||
| Research and development | $10.1M | $19.5M | $70.9M | $101.1M |
| Sales and admin | $10.3M | $11.1M | $13.8M | $20.3M |
| Total operating expenses | $20.5M | $30.7M | $84.7M | $121.4M |
| What was left | ||||
| Operating profit | -$20.5M | -$30.7M | -$84.7M | -$121.4M |
| Profit before tax | -$18.0M | -$28.9M | -$78.9M | -$111.3M |
| Net profit | -$18.0M | -$28.9M | -$78.9M | -$111.3M |
| EBITDA | -$20.4M | -$30.6M | -$84.6M | -$111.2M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace